Peter Honig - Jul 20, 2021 Form 4 Insider Report for Sesen Bio, Inc. (CARM)

Role
Director
Signature
s/ Mark R. Sullivan, as attorney-in-fact
Stock symbol
CARM
Transactions as of
Jul 20, 2021
Transactions value $
$0
Form type
4
Date filed
7/21/2021, 05:37 PM
Next filing
Dec 7, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CARM Stock Option Award $0 +185K $0.00 185K Jul 20, 2021 Common Stock 185K $3.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on July 20, 2021 and vests monthly in equal amounts over a three-year period following the grant date. Based on market analysis by Radford of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion, the compensation committee of Sesen Bio, Inc. (the "Company") recommended to the Company's board of directors, and the board of directors approved, the amount of the initial grant to the reporting person in connection with the reporting person's appointment as a non-employee director.